Cardiovascular Pathophysiology and Pharmacology

Understanding Antihypertensive Drug Classes

Hypertension remains a leading risk factor for cardiovascular disease worldwide. Effective blood‑pressure control relies on a solid grasp of the pharmacologic mechanisms behind each drug class. This section explores the most commonly used antihypertensives, emphasizing how they influence the renin‑angiotensin‑aldosterone system (RAAS), cardiac output, and peripheral resistance.

ACE Inhibitors: Blocking Angiotensin‑II Formation

Key concept: Angiotensin‑converting enzyme (ACE) inhibitors reduce blood pressure by inhibiting the conversion of angiotensin I to the potent vasoconstrictor angiotensin II.

• Resulting vasodilation lowers systemic vascular resistance.
• Decreased aldosterone secretion reduces sodium and water retention.
• Clinical benefits include protection against diabetic nephropathy and reduction of left‑ventricular hypertrophy.

Typical agents: enalapril, lisinopril, ramipril.

Beta‑Blockers: Reducing Cardiac Output

The primary antihypertensive effect of beta blockers stems from reduced heart rate and contractility. By blocking β1‑adrenergic receptors in the myocardium, these drugs decrease cardiac output, which in turn lowers arterial pressure.

• Additional effects: inhibition of renin release from juxtaglomerular cells.
• Commonly used agents: metoprolol, atenolol, carvedilol (which also has α‑blocking activity).
• Indications beyond hypertension: post‑myocardial infarction, heart failure, and certain arrhythmias.

Thiazide Diuretics: Volume Reduction

Thiazide diuretics lower blood pressure primarily by promoting renal sodium and water excretion, thereby decreasing plasma volume and cardiac output.

• Mechanism: inhibition of the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule.
• Long‑term benefits include reduced peripheral resistance due to vascular remodeling.
• Examples: hydrochlorothiazide, chlorthalidone.

Statins and Lipid Management

Elevated low‑density lipoprotein (LDL) cholesterol is a major modifiable risk factor for atherosclerotic cardiovascular disease. Statins are the cornerstone of lipid‑lowering therapy.

Mechanism of Action

Statins inhibit HMG‑CoA reductase in the liver, the rate‑limiting step of cholesterol synthesis. This inhibition leads to:

• Up‑regulation of hepatic LDL receptors, increasing clearance of circulating LDL particles.
• Modest reductions in triglycerides and modest increases in high‑density lipoprotein (HDL).
• Pleiotropic effects such as improved endothelial function and anti‑inflammatory properties.

Common agents include atorvastatin, rosuvastatin, and simvastatin. Dose‑dependent LDL reductions range from 20 % to 60 %.

Cardiac Biomarkers in Acute Myocardial Infarction

Rapid and accurate diagnosis of myocardial infarction (MI) is critical for timely reperfusion therapy. Among the available biomarkers, troponin I rises earliest and is the most specific for myocardial injury.

Why Troponin I?

• Detectable within 3–4 hours of symptom onset.
• Remains elevated for up to 10 days, allowing a broader diagnostic window.
• High cardiac specificity reduces false‑positive results from skeletal muscle injury.

Other markers such as CK‑MB, lactate dehydrogenase, and myoglobin have longer rise times or lower specificity and are therefore used as adjuncts rather than primary diagnostics.

Mechanical Complications of ST‑Elevation Myocardial Infarction (STEMI)

STEMI can lead to several life‑threatening mechanical complications. Understanding the pathophysiology helps clinicians anticipate and manage these events.

Papillary Muscle Rupture

A rupture of the papillary muscle after a STEMI most directly causes severe mitral regurgitation. The loss of papillary support allows the mitral valve leaflets to prolapse into the left atrium during systole, producing a sudden volume overload and pulmonary edema.

• Clinical presentation: acute dyspnea, a new holosystolic murmur, and rapid hemodynamic deterioration.
• Management: emergent surgical repair or replacement of the mitral valve, alongside aggressive afterload reduction.

Other Mechanical Complications (for contrast)

• Free‑wall rupture → cardiac tamponade.
• Interventricular septal defect → left‑to‑right shunt.
• Ventricular aneurysm formation (late complication).

Antiplatelet Therapy: Aspirin’s Role

Platelet aggregation is a pivotal step in arterial thrombosis. Aspirin provides antiplatelet activity by irreversibly inhibiting the COX‑1 enzyme in platelets, which blocks thromboxane A₂ synthesis.

• Effect lasts for the lifespan of the platelet (≈7‑10 days).
• Low‑dose regimens (75‑100 mg daily) are sufficient for cardiovascular protection while minimizing gastrointestinal side effects.
• Often combined with other agents (e.g., P2Y12 inhibitors) in dual‑antiplatelet therapy after percutaneous coronary intervention.

Advanced Cardiac Life Support (ACLS): Adrenergic Stimulation

During cardiac arrest, the drug of choice for stimulating both alpha and beta adrenergic receptors is adrenaline (epinephrine). Its dual action provides:

• Alpha‑mediated peripheral vasoconstriction, which increases coronary and cerebral perfusion pressure during chest compressions.
• Beta‑mediated positive inotropic and chronotropic effects, supporting myocardial contractility.

Standard ACLS protocols recommend 1 mg of intravenous adrenaline every 3‑5 minutes during resuscitation attempts.

Integrating Pharmacology into Clinical Practice

Effective cardiovascular care requires not only knowledge of drug mechanisms but also the ability to apply this information to patient‑specific scenarios.

Case‑Based Application

Case: A 50‑year‑old man with newly diagnosed hypertension is started on a thiazide diuretic.

• Identify the primary antihypertensive mechanism: promoting renal sodium and water excretion, reducing plasma volume.
• Anticipate common side effects: hypokalemia, hyperuricemia, and mild hyperglycemia.
• Consider adjunct therapy if blood pressure remains uncontrolled—adding an ACE inhibitor or a beta blocker can target complementary pathways.

Key Take‑aways for Exam Preparation

• Match each drug class to its principal mechanism (e.g., ACE inhibitors → angiotensin‑II blockade).
• Remember the most specific cardiac biomarker for MI is troponin I.
• Recognize that papillary muscle rupture leads to severe mitral regurgitation, not tamponade.
• Recall that aspirin’s antiplatelet effect is due to irreversible COX‑1 inhibition.
• Adrenaline is the only ACLS drug that stimulates both alpha and beta receptors.

By integrating these concepts, clinicians can make informed therapeutic decisions, improve patient outcomes, and excel in board examinations.